O	0	12	Upregulation	Upregulation	NN	B-NP
O	13	15	of	of	IN	B-PP
O	16	24	vascular	vascular	JJ	B-NP
O	25	36	endothelial	endothelial	JJ	I-NP
O	37	43	growth	growth	NN	I-NP
O	44	50	factor	factor	NN	I-NP
O	51	60	receptors	receptor	NNS	I-NP
O	61	63	is	be	VBZ	B-VP
O	64	74	associated	associate	VBN	I-VP
O	75	79	with	with	IN	B-PP
O	80	88	advanced	advance	VBN	B-NP
B-Cancer	89	102	neuroblastoma	neuroblastoma	NN	I-NP
O	102	103	.	.	.	O

O	104	114	BACKGROUND	BACKGROUND	NN	B-NP
O	114	115	:	:	:	O
O	116	128	Angiogenesis	Angiogenesis	NN	B-NP
O	129	131	is	be	VBZ	B-VP
O	132	141	essential	essential	JJ	B-ADJP
O	142	145	for	for	IN	B-PP
B-Cancer	146	151	tumor	tumor	NN	B-NP
O	152	158	growth	growth	NN	I-NP
O	159	162	and	and	CC	O
O	163	169	relies	rely	VBZ	B-VP
O	170	172	on	on	IN	B-PP
O	173	176	the	the	DT	B-NP
O	177	187	production	production	NN	I-NP
O	188	190	of	of	IN	B-PP
O	191	201	angiogenic	angiogenic	JJ	B-NP
O	202	209	factors	factor	NNS	I-NP
O	209	210	.	.	.	O

O	211	219	Vascular	Vascular	JJ	B-NP
O	220	231	endothelial	endothelial	JJ	I-NP
O	232	238	growth	growth	NN	I-NP
O	239	245	factor	factor	NN	I-NP
O	246	247	(	(	(	O
O	247	251	VEGF	VEGF	NN	B-NP
O	251	252	)	)	)	O
O	253	255	is	be	VBZ	B-VP
O	256	257	a	a	DT	B-NP
O	258	263	major	major	JJ	I-NP
O	264	273	regulator	regulator	NN	I-NP
O	274	276	of	of	IN	B-PP
O	277	289	angiogenesis	angiogenesis	NN	B-NP
O	290	294	that	that	WDT	B-NP
O	295	300	binds	bind	VBZ	B-VP
O	301	303	to	to	TO	B-PP
O	304	312	tyrosine	tyrosine	NN	B-NP
O	313	319	kinase	kinase	NN	I-NP
O	320	329	receptors	receptor	NNS	I-NP
O	330	333	Flt	Flt	NN	I-NP
O	333	334	-	-	HYPH	B-NP
O	334	335	1	1	CD	I-NP
O	336	339	and	and	CC	I-NP
O	340	343	KDR	KDR	NN	I-NP
O	343	344	.	.	.	O

O	345	348	The	The	DT	B-NP
O	349	360	interaction	interaction	NN	I-NP
O	361	363	of	of	IN	B-PP
O	364	368	VEGF	VEGF	NN	B-NP
O	369	372	and	and	CC	O
O	373	376	its	its	PRP$	B-NP
O	377	386	receptors	receptor	NNS	I-NP
O	387	389	at	at	IN	B-PP
O	390	394	gene	gene	NN	B-NP
O	395	398	and	and	CC	I-NP
O	399	406	protein	protein	NN	I-NP
O	407	413	levels	level	NNS	I-NP
O	414	416	in	in	IN	B-PP
B-Cancer	417	430	neuroblastoma	neuroblastoma	NN	B-NP
O	431	438	remains	remain	VBZ	B-VP
O	439	445	widely	widely	RB	B-ADJP
O	446	453	unknown	unknown	JJ	I-ADJP
O	453	454	.	.	.	O

O	455	462	METHODS	METHODS	NNS	B-NP
O	462	463	:	:	:	O
B-Cancer	464	469	Tumor	Tumor	NN	B-NP
I-Cancer	470	476	biopsy	biopsy	NN	I-NP
I-Cancer	477	486	specimens	specimen	NNS	I-NP
O	487	490	and	and	CC	O
B-Organism_substance	491	496	serum	serum	NN	B-NP
O	497	501	were	be	VBD	B-VP
O	502	510	obtained	obtain	VBN	I-VP
O	511	515	from	from	IN	B-PP
O	516	518	37	37	CD	B-NP
B-Cancer	519	532	neuroblastoma	neuroblastoma	NN	I-NP
O	533	541	patients	patient	NNS	I-NP
O	541	542	;	;	:	O
B-Multi-tissue_structure	543	550	adrenal	adrenal	JJ	B-NP
I-Multi-tissue_structure	551	557	biopsy	biopsy	NN	I-NP
I-Multi-tissue_structure	558	566	sections	section	NNS	I-NP
O	567	570	and	and	CC	I-NP
B-Organism_substance	571	575	sera	serum	NNS	I-NP
O	576	578	of	of	IN	B-PP
O	579	580	7	7	CD	B-NP
O	581	587	normal	normal	JJ	I-NP
O	588	596	children	child	NNS	I-NP
O	597	603	served	serve	VBD	B-VP
O	604	606	as	as	IN	B-PP
O	607	615	controls	control	NNS	B-NP
O	615	616	.	.	.	O

B-Cancer	617	623	Biopsy	Biopsy	NN	B-NP
I-Cancer	624	633	specimens	specimen	NNS	I-NP
O	634	638	were	be	VBD	B-VP
O	639	647	examined	examine	VBN	I-VP
O	648	650	by	by	IN	B-PP
O	651	655	real	real	JJ	B-NP
O	655	656	-	-	HYPH	I-NP
O	656	660	time	time	NN	I-NP
O	661	668	reverse	reverse	JJ	I-NP
O	669	682	transcription	transcription	NN	I-NP
O	683	693	polymerase	polymerase	NN	I-NP
O	694	699	chain	chain	NN	I-NP
O	700	708	reaction	reaction	NN	I-NP
O	709	710	(	(	(	O
O	710	712	RT	RT	NN	B-NP
O	712	713	-	-	HYPH	B-NP
O	713	716	PCR	PCR	NN	I-NP
O	716	717	)	)	)	O
O	718	721	and	and	CC	O
O	722	729	Western	Western	NN	B-NP
O	730	738	blotting	blotting	NN	I-NP
O	738	739	;	;	:	O
B-Organism_substance	740	745	serum	serum	NN	B-NP
O	746	749	was	be	VBD	B-VP
O	750	758	analyzed	analyze	VBN	I-VP
O	759	761	by	by	IN	B-PP
O	762	768	enzyme	enzyme	NN	B-NP
O	768	769	-	-	HYPH	O
O	769	775	linked	link	VBN	B-NP
O	776	789	immunosorbent	immunosorbent	NN	I-NP
O	790	795	assay	assay	NN	I-NP
O	796	797	(	(	(	O
O	797	802	ELISA	ELISA	NN	B-NP
O	802	803	)	)	)	O
O	803	804	.	.	.	O

O	805	809	VEGF	VEGF	NN	B-NP
O	809	810	-	-	HYPH	I-NP
O	810	811	A	A	NN	I-NP
O	811	812	(	(	(	O
O	812	815	165	165	CD	B-NP
O	815	816	)	)	)	O
O	816	817	,	,	,	O
O	818	819	B	B	NN	B-NP
O	819	820	,	,	,	O
O	821	822	C	C	NN	B-NP
O	822	823	,	,	,	O
O	824	827	Flt	Flt	NN	B-NP
O	827	828	-	-	HYPH	B-NP
O	828	829	1	1	CD	I-NP
O	829	830	,	,	,	O
O	831	834	and	and	CC	O
O	835	838	KDR	KDR	NN	B-NP
O	839	843	were	be	VBD	B-VP
O	844	852	analyzed	analyze	VBN	I-VP
O	852	853	.	.	.	O

O	854	861	RESULTS	RESULTS	NNS	B-NP
O	861	862	:	:	:	O
O	863	867	VEGF	VEGF	NN	B-NP
O	868	876	isoforms	isoform	NNS	I-NP
O	877	880	and	and	CC	O
O	881	884	its	its	PRP$	B-NP
O	885	894	receptors	receptor	NNS	I-NP
O	894	895	'	'	POS	B-NP
O	896	900	mRNA	mRNA	NN	I-NP
O	901	905	were	be	VBD	B-VP
O	906	915	expressed	express	VBN	I-VP
O	916	918	in	in	IN	B-PP
B-Cancer	919	932	neuroblastoma	neuroblastoma	NN	B-NP
O	933	936	and	and	CC	I-NP
O	937	944	control	control	NN	I-NP
B-Tissue	945	952	tissues	tissue	NNS	I-NP
O	952	953	.	.	.	O

O	954	961	Whereas	Whereas	IN	B-SBAR
O	962	965	the	the	DT	B-NP
O	966	973	ligands	ligand	NNS	I-NP
O	974	978	were	be	VBD	B-VP
O	979	988	increased	increase	VBN	I-VP
O	989	991	in	in	IN	B-PP
O	992	998	stages	stage	NNS	B-NP
O	999	1002	III	III	CD	B-NP
O	1003	1006	and	and	CC	I-NP
O	1007	1009	IV	IV	CD	I-NP
O	1009	1010	,	,	,	O
O	1011	1014	the	the	DT	B-NP
O	1015	1024	receptors	receptor	NNS	I-NP
O	1025	1029	were	be	VBD	B-VP
O	1030	1041	upregulated	upregulate	VBN	I-VP
O	1042	1044	in	in	IN	B-PP
O	1045	1050	stage	stage	NN	B-NP
O	1051	1054	III	III	CD	I-NP
O	1055	1059	only	only	RB	B-ADVP
O	1059	1060	.	.	.	O

O	1061	1063	At	At	IN	B-PP
O	1064	1071	protein	protein	NN	B-NP
O	1072	1077	level	level	NN	I-NP
O	1077	1078	,	,	,	O
O	1079	1083	VEGF	VEGF	NN	B-NP
O	1083	1084	-	-	HYPH	O
O	1084	1085	B	B	NN	B-NP
O	1086	1089	and	and	CC	O
O	1090	1091	C	C	NN	B-NP
O	1091	1092	,	,	,	O
O	1093	1096	Flt	Flt	NN	B-NP
O	1096	1097	-	-	HYPH	B-NP
O	1097	1098	1	1	CD	I-NP
O	1098	1099	,	,	,	O
O	1100	1103	and	and	CC	O
O	1104	1107	KDR	KDR	NN	B-NP
O	1108	1112	were	be	VBD	B-VP
O	1113	1116	not	not	RB	B-ADJP
O	1117	1127	detectable	detectable	JJ	I-ADJP
O	1128	1130	in	in	IN	B-PP
B-Organism_substance	1131	1137	tissue	tissue	NN	B-NP
I-Organism_substance	1138	1145	lysates	lysate	NNS	I-NP
O	1145	1146	,	,	,	O
O	1147	1154	whereas	whereas	IN	O
O	1155	1159	VEGF	VEGF	NN	B-NP
O	1159	1160	-	-	HYPH	I-NP
O	1160	1161	A	A	NN	I-NP
O	1162	1165	was	be	VBD	B-VP
O	1166	1175	increased	increase	VBN	I-VP
O	1176	1178	in	in	IN	B-PP
O	1179	1185	stages	stage	NNS	B-NP
O	1186	1189	III	III	CD	B-NP
O	1190	1193	and	and	CC	I-NP
O	1194	1196	IV	IV	CD	I-NP
O	1196	1197	.	.	.	O

B-Organism_substance	1198	1203	Serum	Serum	NN	B-NP
O	1204	1208	VEGF	VEGF	NN	I-NP
O	1209	1216	protein	protein	NN	I-NP
O	1217	1223	levels	level	NNS	I-NP
O	1224	1228	were	be	VBD	B-VP
O	1229	1240	upregulated	upregulate	VBN	I-VP
O	1241	1243	in	in	IN	B-PP
O	1244	1249	stage	stage	NN	B-NP
O	1250	1253	III	III	CD	I-NP
O	1253	1254	.	.	.	O

O	1255	1266	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1266	1267	:	:	:	O
O	1268	1272	VEGF	VEGF	NN	B-NP
O	1272	1273	-	-	HYPH	B-NP
O	1273	1274	A	A	NN	I-NP
O	1274	1275	(	(	(	O
O	1275	1278	165	165	CD	B-NP
O	1278	1279	)	)	)	O
O	1280	1282	is	be	VBZ	B-VP
O	1283	1286	one	one	CD	B-NP
O	1287	1289	of	of	IN	B-PP
O	1290	1293	the	the	DT	B-NP
O	1294	1299	major	major	JJ	I-NP
O	1300	1312	angiogenesis	angiogenesis	NN	I-NP
O	1313	1323	regulators	regulator	NNS	I-NP
O	1324	1329	among	among	IN	B-PP
O	1330	1333	the	the	DT	B-NP
O	1334	1341	ligands	ligand	NNS	I-NP
O	1341	1342	'	'	POS	B-NP
O	1343	1349	family	family	NN	I-NP
O	1350	1352	of	of	IN	B-PP
O	1353	1357	VEGF	VEGF	NN	B-NP
O	1357	1358	,	,	,	O
O	1359	1366	whereas	whereas	IN	O
O	1367	1370	its	its	PRP$	B-NP
O	1371	1380	receptors	receptor	NNS	I-NP
O	1381	1384	KDR	KDR	NN	I-NP
O	1384	1385	,	,	,	O
O	1386	1389	and	and	CC	O
O	1390	1394	most	most	RBS	B-ADVP
O	1395	1403	probably	probably	RB	B-NP
O	1404	1407	Flt	Flt	NN	I-NP
O	1407	1408	-	-	HYPH	B-NP
O	1408	1409	1	1	CD	I-NP
O	1409	1410	,	,	,	O
O	1411	1414	may	may	MD	B-VP
O	1415	1425	contribute	contribute	VB	I-VP
O	1426	1428	to	to	TO	B-PP
O	1429	1430	a	a	DT	B-NP
O	1431	1435	poor	poor	JJ	I-NP
O	1436	1445	prognosis	prognosis	NN	I-NP
O	1446	1447	(	(	(	O
O	1447	1457	angiogenic	angiogenic	JJ	O
O	1457	1458	)	)	)	O
O	1459	1468	phenotype	phenotype	NN	B-NP
O	1468	1469	,	,	,	O
O	1470	1472	as	as	IN	B-SBAR
O	1473	1482	indicated	indicate	VBN	B-VP
O	1483	1485	by	by	IN	B-PP
O	1486	1491	their	their	PRP$	B-NP
O	1492	1503	upregulated	upregulate	VBN	I-NP
O	1504	1508	MRNA	MRNA	NN	I-NP
O	1509	1515	levels	level	NNS	I-NP
O	1516	1518	in	in	IN	B-PP
B-Cancer	1519	1524	stage	stage	NN	B-NP
I-Cancer	1525	1528	III	III	CD	I-NP
I-Cancer	1529	1542	neuroblastoma	neuroblastoma	NN	I-NP
O	1542	1543	.	.	.	O

O	1544	1548	VEGF	VEGF	NN	B-NP
O	1548	1549	-	-	HYPH	I-NP
O	1549	1550	A	A	NN	I-NP
O	1550	1551	(	(	(	O
O	1551	1554	165	165	CD	B-NP
O	1554	1555	)	)	)	O
O	1556	1562	mainly	mainly	RB	B-ADVP
O	1563	1574	contributes	contribute	VBZ	B-VP
O	1575	1577	to	to	TO	B-PP
O	1578	1587	increased	increase	VBN	B-NP
B-Organism_substance	1588	1593	serum	serum	NN	I-NP
O	1594	1598	VEGF	VEGF	NN	I-NP
O	1599	1605	levels	level	NNS	I-NP
O	1606	1609	and	and	CC	O
O	1610	1613	may	may	MD	B-VP
O	1614	1619	serve	serve	VB	I-VP
O	1620	1622	as	as	IN	B-PP
O	1623	1624	a	a	DT	B-NP
O	1625	1635	diagnostic	diagnostic	JJ	I-NP
O	1636	1640	tool	tool	NN	I-NP
O	1641	1643	in	in	IN	B-PP
O	1644	1652	advanced	advance	VBN	B-NP
O	1652	1653	-	-	HYPH	I-NP
O	1653	1658	stage	stage	NN	I-NP
B-Cancer	1659	1672	neuroblastoma	neuroblastoma	NN	I-NP
O	1672	1673	.	.	.	O

